Brought to you by 
Daiichi Sankyo gets Japanese rights to Amgen's denosumab
19 Jul 2017
Executive Summary
Daiichi Sankyo has licensed exclusive Japanese development and marketing rights to Amgen's Phase III denosumab for post-menopausal osteoporosis, bone metastases, treatment-induced bone loss, multiple myeloma, and bone erosions in patients with rheumatoid arthritis.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Daiichi Sankyo gets Japanese rights to Amgen's denosumab
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice